What is the role of the epithelial sodium channel (ENaC) in nephrotic syndrome?

Role of ENaC in Nephrotic Syndrome

The epithelial sodium channel (ENaC) is proteolytically activated by aberrantly filtered urinary serine proteases in nephrotic syndrome, driving sodium retention, edema formation, and low-renin hypertension independent of aldosterone excess. 1, 2

Pathophysiologic Mechanism

Proteolytic Activation Pathway

• When the glomerular filtration barrier is damaged in nephrotic syndrome, serine proteases (normally excluded from urine) are aberrantly filtered into the tubular lumen 2, 3
• These urinary serine proteases cleave ENaC subunits—specifically the α- and γ-subunits at both proximal and distal cleavage sites—releasing inhibitory peptides from the channel's ectodomain 1
• Cleavage at the distal site of γ-ENaC is the predominant activation mechanism, as demonstrated in both murine experimental nephrotic syndrome and human nephrectomy specimens 1
• This proteolytic activation dramatically increases ENaC-mediated sodium reabsorption in the collecting duct, independent of aldosterone signaling 2

Identity of Activating Proteases

The specific proteases responsible remain incompletely defined, with evidence pointing to redundant, multiple serine proteases rather than a single culprit:

• Plasmin was initially identified as a key activator: it is highly abundant in nephrotic urine, directly activates ENaC currents in vitro, and its inhibitors abolish urinary protease activity 3
• However, plasminogen-deficient mice with experimental nephrotic syndrome still develop ENaC-mediated sodium retention and edema, proving plasmin is not essential and that other proteases compensate in its absence 4
• Factor VII activating protease (FSAP) is present in active form in nephrotic urine and activates ENaC in vitro via the γ-ENaC cleavage site, but FSAP-deficient mice are similarly not protected from sodium retention 5
• Urokinase-type plasminogen activator likely converts filtered plasminogen to plasmin in the tubule, contributing to but not solely mediating the effect 2, 3

Clinical Consequences

• Sodium retention occurs via amiloride-sensitive ENaC activation, leading to positive sodium balance, weight gain, and ascites 1, 4
• Low-renin hypertension develops because sodium retention is primary (tubular) rather than secondary to underfill, suppressing the renin-angiotensin-aldosterone system 2
• The process is aprotinin-sensitive: serine protease inhibition with aprotinin prevents both ENaC cleavage and sodium retention in experimental models 1, 4

Therapeutic Implications

ENaC Blockade as Targeted Therapy

• Amiloride (an ENaC blocker) alleviates nephrotic sodium retention and low-renin hypertension with high efficacy across experimental models, human case reports, and small intervention trials 2
• Amiloride or triamterene should be considered as potassium-sparing diuretics when combining loop diuretics with spironolactone in diuretic-resistant edema, particularly given the mechanistic rationale for ENaC blockade 6, 7, 2
• This represents a personalized, mechanism-based approach to nephrotic edema rather than empiric diuretic escalation alone 2

Integration with Guideline-Directed Therapy

While KDIGO guidelines prioritize loop diuretics as first-line for edema 6, 7, the ENaC activation mechanism provides rationale for:

• Adding amiloride when edema is resistant to loop diuretics, exploiting the distinct distal tubular mechanism 6, 7, 2
• Monitoring for hyperkalemia when combining amiloride with RAS blockade (ACE inhibitors/ARBs), using potassium binders if needed rather than reducing the ARB dose 6
• Recognizing that sodium retention in nephrotic syndrome is primary (tubular) rather than secondary to underfill, which explains why aggressive diuresis is often needed 2

Common Pitfalls

• Do not assume aldosterone excess is driving sodium retention in nephrotic syndrome; ENaC activation is aldosterone-independent and mediated by urinary proteases 2
• Do not rely solely on spironolactone for potassium-sparing effect; amiloride directly targets the activated ENaC mechanism and may be more effective 6, 2
• Recognize that multiple redundant proteases are involved, so targeting a single protease (e.g., plasmin inhibition) will not prevent sodium retention 5, 4